Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS8 | Q16651 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 11/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226725 | 0.94 | PRSS8 (0.61) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8232453 | 0.93 | PRSS8 (0.56) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8232769 | 0.93 | PRSS8 (0.59) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL12617770 | 0.93 | PRSS8 (0.64) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8232766 | 0.92 | PRSS8 (0.58) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8234691 | 0.92 | PRSS8 (0.64) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8226707 | 0.92 | PRSS8 (0.55) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8230408 | 0.92 | PRSS8 (0.58) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8225018 | 0.91 | PRSS8 (0.57) | PRSS8CTSSPRSS1PRSS2PRSS3 | |
| SCHEMBL8230423 | 0.90 | PRSS8 (0.68) | PRSS8CTSSPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | PRSS8 2/4885CTSS 8/4885PRSS1 1/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | PRSS8 2/4885CTSS 8/4885PRSS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.